Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 45,351 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $148.20, for a total value of $6,721,018.20. Following the completion of the transaction, the chief executive officer now owns 278,678 shares in the company, valued at approximately $41,300,079.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of RGEN opened at $150.27 on Wednesday. The stock’s 50-day simple moving average is $148.33 and its 200 day simple moving average is $122.57. Repligen Co. has a 52-week low of $72.32 and a 52-week high of $159.97. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 259.09, a price-to-earnings-growth ratio of 4.04 and a beta of 1.12. The company has a debt-to-equity ratio of 0.22, a quick ratio of 13.90 and a current ratio of 15.48.
Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.14. The firm had revenue of $87.46 million for the quarter, compared to analysts’ expectations of $78.11 million. Repligen had a return on equity of 5.93% and a net margin of 10.23%. On average, research analysts forecast that Repligen Co. will post 1.28 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Steward Partners Investment Advisory LLC raised its stake in shares of Repligen by 48.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 200 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 65 shares during the last quarter. Blair William & Co. IL raised its stake in Repligen by 1.3% in the 2nd quarter. Blair William & Co. IL now owns 6,149 shares of the biotechnology company’s stock worth $760,000 after acquiring an additional 80 shares during the last quarter. Prospera Financial Services Inc grew its position in Repligen by 1.4% during the 2nd quarter. Prospera Financial Services Inc now owns 7,037 shares of the biotechnology company’s stock worth $870,000 after purchasing an additional 94 shares during the period. Mercer Global Advisors Inc. ADV grew its position in shares of Repligen by 3.7% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 2,748 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 98 shares during the period. Finally, Flagship Harbor Advisors LLC grew its position in shares of Repligen by 39.9% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 526 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 97.87% of the company’s stock.
Several analysts have recently weighed in on RGEN shares. Stifel Nicolaus boosted their price target on Repligen from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, May 27th. HC Wainwright upped their target price on Repligen from $151.00 to $168.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Finally, BidaskClub downgraded Repligen from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $139.50.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.